发现另一块蛋糕:RIT1M90I是非小细胞肺癌的可操作驱动因素
Cheng Pei Wu1, Aria Vaishnavi1,2
1Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer research
|September 2, 2025
概括
两项新的研究显示RIT1M90I是肺腺癌的关键驱动因素,促进药物耐药性. 鼠标模型显示RIT1突变瘤对SHP2或RAS抑制剂有反应,为治疗提供了新的途径.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 肺腺癌是精确瘤学的模型,但未知的分子驱动因素限制了向治疗的成功.
- 获得的耐药性仍然是治疗肺腺癌的一个重大挑战.
研究的目的:
- 将RIT1M90I描述为肺腺癌中获得药物耐药性的新驱动因素和促进者.
- 为研究RIT1驱动的肺癌引入和验证新的小鼠模型.
主要方法:
- 为RIT1M90I生成和表征独特的小鼠模型.
- 在RIT1突变肺瘤中评估瘤潜伏期和药物敏感性.
- 对SHP2和RAS三复合抑制剂的反应评估.
主要成果:
- 在肺腺癌中,RIT1M90I被确定为一种新的可操作的驱动因素.
- 产生的小鼠模型对SHP2或RAS三复合抑制剂具有敏感性.
- 在RIT1突变的肺瘤中,对向抑制剂的敏感性已被证明.
结论:
- RIT1M90I是肺腺癌的重要驱动因素,也是获得药物耐药性的媒介.
- 新的RIT1驱动肺癌模型对于治疗策略的临床前测试有价值.
- 针对RIT1突变提供了一种有希望的方法来克服肺腺癌的耐药性.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K